S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.83 (+0.12%)
AAPL   123.09 (+0.30%)
MSFT   215.32 (-0.41%)
FB   287.61 (+0.37%)
GOOGL   1,826.96 (+1.76%)
AMZN   3,205.34 (-0.46%)
TSLA   568.29 (-2.82%)
NVDA   541.77 (+1.15%)
BABA   261.08 (-1.11%)
CGC   28.16 (+5.67%)
GE   10.42 (+2.66%)
MU   69.13 (+3.06%)
AMD   93.76 (+1.22%)
T   29.08 (+0.73%)
NIO   47.89 (+5.58%)
F   9.19 (-0.54%)
ACB   10.92 (+12.00%)
NFLX   503.55 (-0.20%)
BA   223.79 (+5.06%)
GILD   61.16 (+0.07%)
DIS   153.50 (+2.72%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.83 (+0.12%)
AAPL   123.09 (+0.30%)
MSFT   215.32 (-0.41%)
FB   287.61 (+0.37%)
GOOGL   1,826.96 (+1.76%)
AMZN   3,205.34 (-0.46%)
TSLA   568.29 (-2.82%)
NVDA   541.77 (+1.15%)
BABA   261.08 (-1.11%)
CGC   28.16 (+5.67%)
GE   10.42 (+2.66%)
MU   69.13 (+3.06%)
AMD   93.76 (+1.22%)
T   29.08 (+0.73%)
NIO   47.89 (+5.58%)
F   9.19 (-0.54%)
ACB   10.92 (+12.00%)
NFLX   503.55 (-0.20%)
BA   223.79 (+5.06%)
GILD   61.16 (+0.07%)
DIS   153.50 (+2.72%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.83 (+0.12%)
AAPL   123.09 (+0.30%)
MSFT   215.32 (-0.41%)
FB   287.61 (+0.37%)
GOOGL   1,826.96 (+1.76%)
AMZN   3,205.34 (-0.46%)
TSLA   568.29 (-2.82%)
NVDA   541.77 (+1.15%)
BABA   261.08 (-1.11%)
CGC   28.16 (+5.67%)
GE   10.42 (+2.66%)
MU   69.13 (+3.06%)
AMD   93.76 (+1.22%)
T   29.08 (+0.73%)
NIO   47.89 (+5.58%)
F   9.19 (-0.54%)
ACB   10.92 (+12.00%)
NFLX   503.55 (-0.20%)
BA   223.79 (+5.06%)
GILD   61.16 (+0.07%)
DIS   153.50 (+2.72%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.83 (+0.12%)
AAPL   123.09 (+0.30%)
MSFT   215.32 (-0.41%)
FB   287.61 (+0.37%)
GOOGL   1,826.96 (+1.76%)
AMZN   3,205.34 (-0.46%)
TSLA   568.29 (-2.82%)
NVDA   541.77 (+1.15%)
BABA   261.08 (-1.11%)
CGC   28.16 (+5.67%)
GE   10.42 (+2.66%)
MU   69.13 (+3.06%)
AMD   93.76 (+1.22%)
T   29.08 (+0.73%)
NIO   47.89 (+5.58%)
F   9.19 (-0.54%)
ACB   10.92 (+12.00%)
NFLX   503.55 (-0.20%)
BA   223.79 (+5.06%)
GILD   61.16 (+0.07%)
DIS   153.50 (+2.72%)
Log in
OTCMKTS:BIOYF

BioSyent Competitors

$5.41
0.00 (0.00 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.41
Now: $5.41
$5.41
50-Day Range
$5.23
MA: $5.33
$5.55
52-Week Range
$2.15
Now: $5.41
$5.74
VolumeN/A
Average Volume5,691 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BioSyent (OTCMKTS:BIOYF) Vs. ABSCF, AGFAF, BOSQF, PHGE, CRTPF, and DBCCF

Should you be buying BIOYF stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to BioSyent, including AB Science (ABSCF), AgraFlora Organics International (AGFAF), Better Plant Sciences (BOSQF), BiomX (PHGE), Cardiol Therapeutics (CRTPF), and Decibel Cannabis (DBCCF).

BioSyent (OTCMKTS:BIOYF) and AB Science (OTCMKTS:ABSCF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares BioSyent and AB Science's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSyentN/AN/AN/A
AB ScienceN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for BioSyent and AB Science, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSyent01002.00
AB Science00103.00

BioSyent currently has a consensus price target of $7.00, suggesting a potential upside of 29.47%. Given BioSyent's higher probable upside, equities research analysts clearly believe BioSyent is more favorable than AB Science.

Earnings & Valuation

This table compares BioSyent and AB Science's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSyentN/AN/AN/AN/AN/A
AB ScienceN/AN/AN/AN/AN/A

Summary

AB Science beats BioSyent on 2 of the 3 factors compared between the two stocks.

AgraFlora Organics International (OTCMKTS:AGFAF) and BioSyent (OTCMKTS:BIOYF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations for AgraFlora Organics International and BioSyent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AgraFlora Organics International00103.00
BioSyent01002.00

AgraFlora Organics International currently has a consensus target price of $0.38, indicating a potential upside of 1,307.41%. BioSyent has a consensus target price of $7.00, indicating a potential upside of 29.47%. Given AgraFlora Organics International's stronger consensus rating and higher possible upside, analysts plainly believe AgraFlora Organics International is more favorable than BioSyent.

Valuation & Earnings

This table compares AgraFlora Organics International and BioSyent's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgraFlora Organics InternationalN/AN/AN/AN/AN/A
BioSyentN/AN/AN/AN/AN/A

Profitability

This table compares AgraFlora Organics International and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AgraFlora Organics InternationalN/AN/AN/A
BioSyentN/AN/AN/A

Summary

AgraFlora Organics International beats BioSyent on 3 of the 3 factors compared between the two stocks.

Better Plant Sciences (OTC:BOSQF) and BioSyent (OTCMKTS:BIOYF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares Better Plant Sciences and BioSyent's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better Plant SciencesN/AN/AN/AN/AN/A
BioSyentN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Better Plant Sciences and BioSyent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Better Plant Sciences0000N/A
BioSyent01002.00

BioSyent has a consensus price target of $7.00, indicating a potential upside of 29.47%. Given BioSyent's higher probable upside, analysts clearly believe BioSyent is more favorable than Better Plant Sciences.

Profitability

This table compares Better Plant Sciences and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Better Plant SciencesN/AN/AN/A
BioSyentN/AN/AN/A

Summary

BioSyent beats Better Plant Sciences on 1 of the 1 factors compared between the two stocks.

BiomX (NYSEMKT:PHGE) and BioSyent (OTCMKTS:BIOYF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares BiomX and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiomXN/AN/AN/A
BioSyentN/AN/AN/A

Earnings and Valuation

This table compares BiomX and BioSyent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiomXN/AN/AN/AN/AN/A
BioSyentN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for BiomX and BioSyent, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiomX00103.00
BioSyent01002.00

BioSyent has a consensus price target of $7.00, suggesting a potential upside of 29.47%.

Summary

BiomX beats BioSyent on 2 of the 2 factors compared between the two stocks.

Cardiol Therapeutics (OTCMKTS:CRTPF) and BioSyent (OTCMKTS:BIOYF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares Cardiol Therapeutics and BioSyent's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/AN/AN/AN/A
BioSyentN/AN/AN/AN/AN/A

Profitability

This table compares Cardiol Therapeutics and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiol TherapeuticsN/AN/AN/A
BioSyentN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Cardiol Therapeutics and BioSyent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiol Therapeutics0000N/A
BioSyent01002.00

BioSyent has a consensus target price of $7.00, suggesting a potential upside of 29.47%. Given BioSyent's higher probable upside, analysts plainly believe BioSyent is more favorable than Cardiol Therapeutics.

Summary

BioSyent beats Cardiol Therapeutics on 1 of the 1 factors compared between the two stocks.

Decibel Cannabis (OTCMKTS:DBCCF) and BioSyent (OTCMKTS:BIOYF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Decibel Cannabis and BioSyent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Decibel Cannabis01002.00
BioSyent01002.00

Decibel Cannabis presently has a consensus target price of $0.15, indicating a potential upside of 165.58%. BioSyent has a consensus target price of $7.00, indicating a potential upside of 29.47%. Given Decibel Cannabis' higher possible upside, research analysts plainly believe Decibel Cannabis is more favorable than BioSyent.

Profitability

This table compares Decibel Cannabis and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Decibel CannabisN/AN/AN/A
BioSyentN/AN/AN/A

Earnings & Valuation

This table compares Decibel Cannabis and BioSyent's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel CannabisN/AN/AN/AN/AN/A
BioSyentN/AN/AN/AN/AN/A

Summary

Decibel Cannabis beats BioSyent on 1 of the 1 factors compared between the two stocks.


BioSyent Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABSCF
AB Science
0.7$12.25flat$0.00N/A0.00
AGFAF
AgraFlora Organics International
1.5$0.03flat$0.00N/A0.00Increase in Short Interest
BOSQF
Better Plant Sciences
0.8$0.05flat$0.00N/A0.00
PHGE
BiomX
0.5N/AN/A$0.00N/A0.00High Trading Volume
CRTPF
Cardiol Therapeutics
0.5$2.09flat$0.00N/A0.00Increase in Short Interest
DBCCF
Decibel Cannabis
1.1$0.06flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Heavy News Reporting
WSLFF
Halo Labs
1.3$0.06flat$0.00N/A0.00High Trading Volume
KSPHF
Kissei Pharmaceutical
0.4$20.12flat$0.00N/A0.00
PDDPF
Medexus Pharmaceuticals
1.5$3.22flat$0.00N/A0.00Heavy News Reporting
MPXOF
MPX International
0.5$0.06flat$0.00N/A0.00Increase in Short Interest
Heavy News Reporting
SGIOF
Shionogi & Co., Ltd.
0.3$53.60flat$0.00N/A0.00High Trading Volume
TAIPY
Taisho Pharmaceutical
0.4$16.01flat$0.00N/A0.00
GCAN
The Greater Cannabis
0.5$0.00flat$0.00N/A0.00High Trading Volume
TLLTF
TILT
1.5$0.30flat$0.00N/A0.00High Trading Volume
CANSF
Willow Biosciences
0.6$0.45flat$0.00N/A0.00High Trading Volume
Decrease in Short Interest
Heavy News Reporting
ZBISF
Zenabis Global
0.5$0.05flat$0.00N/A0.00
This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.